Abstract: The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.

Abstract: The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.

Abstract: A mixing agitator, for industrial use in mixing processes, that overcomes disadvantages associated with glass coated mixing agitators in the prior art. In particular, the mixing agitator includes a glass coated metal hub radially symmetrical about a central axis. The hub is at least partially embedded within a fluorinated polymer. The fluorinated polymer extends beyond the hub and forms agitator blades that may be reinforced. The hub has a centrally located receiving portion for receiving a drive shaft for rotating the agitator. The agitator is lighter weight than prior art glass coated steel agitators yet still has excellent chemical resistance and good temperature resistance. The agitator of the invention reduces likelihood of glass damage and permits agitator blade shapes not useable by glass coated agitators in the prior art. The invention also includes a mixing apparatus incorporating the hub and a method for mixing using the agitator.

Abstract: A mixing agitator, for industrial use in mixing processes, that overcomes disadvantages associated with glass coated mixing agitators in the prior art. In particular, the mixing agitator includes a glass coated metal hub radially symmetrical about a central axis. The hub is at least partially embedded within a fluorinated polymer. The fluorinated polymer extends beyond the hub and forms agitator blades that may be reinforced. The hub has a centrally located receiving portion for receiving a drive shaft for rotating the agitator. The agitator is lighter weight than prior art glass coated steel agitators yet still has excellent chemical resistance and good temperature resistance. The agitator of the invention reduces likelihood of glass damage and permits agitator blade shapes not useable by glass coated agitators in the prior art. The invention also includes a mixing apparatus incorporating the hub and a method for mixing using the agitator.

Abstract: The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.

Abstract: The present disclosure provides oral dosage forms comprising an antiplatelet agent and an enterically coated acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an enterically coated acid inhibitor.

Abstract: The present disclosure provides oral dosage forms comprising an antiplatelet agent and an acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an acid inhibitor.

Abstract: A retaining member for a surgical instrument insert is described. The instrument insert includes a retaining member which is free to move along the shaft before the insert is attached to the handle. The retaining member comprises a resilient member integrally formed with the retaining member. The resilient member can engage the surgical instrument insert shaft and act to prevent the retaining member falling off before the insert is attached to the handle. Because the resilient member is integrally formed the cost of manufacture is reduced. In another embodiment, a surgical instrument insert is provided wherein a proximal portion of the outer shaft is manufactured from an insulating material. The insulating material can be cheaper than the aluminum conventionally used. As a further advantage this also reduces the risk of electric shock and bums when used in an electrically live environment.

Abstract: The present invention provides a finings formulation comprising pectin and methods of using pectin in a fining process to produce fined beverages, particularly beers.

Abstract: There are methods and apparatus, including computer program products, for managing hierarchical reference data. There is a Web page for access by a user, where the Web page includes (i) data representing a hierarchy and (ii) rules defining modifications that are permitted to be made to data. The user is enabled to make a real-time modification to the data based on the rules.

Abstract: There are methods and apparatus, including computer program products, for managing hierarchical reference data. There is a Web page for access by a user, where the Web page includes (i) data representing a hierarchy and (ii) rules defining modifications that are permitted to be made to data. The user is enabled to make a real-time modification to the data based on the rules.

Abstract: There are methods and apparatus, including computer program products, for managing hierarchical reference data. There is a Web page for access by a user, where the Web page includes (i) data representing a hierarchy and (ii) rules defining modifications that are permitted to be made to data. The user is enabled to make a real-time modification to the data based on the rules.

Abstract: Methods and compositions are provided for at least slowing the progression of a filovirus mediated disease condition in a host. In the subject methods, an effective amount of an agent that at least reduces the amount of folate receptor mediated filovirus cell entry is administered to the host. The subject methods find use in both the prevention and treatment of filovirus associated disease conditions, including Marburg and Ebola-Zaire virus mediated disease conditions.

Abstract: The present disclosure provides enteric coated capsules and orally dissolving films comprising non-steroidal anti-inflammatory drugs and acid inhibitors, as well as methods of treating treatment humans for pain and/or inflammation while reducing gastrointestinal side effects.

Abstract: The present disclosure provides oral dosage forms comprising an antiplatelet agent and an enterically coated acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an enterically coated acid inhibitor.

Abstract: The present invention provides a finings formulation comprising pectin and methods of using pectin in a fining process to produce fined beverages, particularly beers.

Abstract: The present disclosure provides oral dosage forms comprising an antiplatelet agent and an acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an acid inhibitor.

Abstract: The present disclosure provides enteric coated capsules and orally dissolving films comprising non-steroidal anti-inflammatory drugs and acid inhibitors, as well as methods of treating treatment humans for pain and/or inflammation while reducing gastrointestinal side effects.

Abstract: Methods and compositions are provided for at least slowing the progression of a filovirus mediated disease condition in a host. In the subject methods, an effective amount of an agent that at least reduces the amount of folate receptor mediated filovirus cell entry is administered to the host. The subject methods find use in both the prevention and treatment of filovirus associated disease conditions, including Marburg and Ebola-Zaire virus mediated disease conditions.

Abstract: Methods and compositions are provided for at least slowing the progression of a filovirus mediated disease condition in a host. In the subject methods, an effective amount of an agent that at least reduces the amount of folate receptor mediated filovirus cell entry is administered to the host. The subject methods find use in both the prevention and treatment of filovirus associated disease conditions, including Marburg and Ebola-Zaire virus mediated disease conditions.